Dublin, Ireland, 4th March 2009
AGI Therapeutics to present at Cowen and Company
29th Annual Health Care Conference in Boston -- 1.40 p.m. EST, Tuesday
17 March, 2009 --
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that the Company's Chief Executive Officer, Dr. John Devane, will present a corporate overview of the Company at the Cowen and Company 29th Annual Health Care Conference in Boston. The conference will be held at the Boston Marriott, Copley Place. AGI will present on Monday 17 March at 1.40 p.m. EST (6.45 p.m. GMT), the presentation will be available via webcast on Cowen and Company's website. A copy of the presentation will be available after the event on the AGI website at www.agitherapeutics.com under the "Investors: Publications" tab.
Contact Information
AGI Therapeutics
David Kelly, Chief Financial Officer
Tel: +353 1 449 3254
Financial Dynamics - UK
Jonathan Birt/John Dineen
Tel: +44 (0) 20 7269 7182
Financial Dynamics - Ireland
Niamh Lyons
Tel: +353 1 663 3602
For further information please see www.agitherapeutics.com.
Notes to Editors:
About AGI Therapeutics plc
AGI is a speciality pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastro-intestinal (GI) diseases and disorders. AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
The Company has a portfolio of product candidates derived from its Known
Molecular Entity (KME™) approach to drug re-profiling and development.
The Company's lead product candidate, RezularTM, is an orally administered
multiple mechanism intestinal regulator, a first-in-class mechanism for
the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).
KME is a re-profiling methodology used by the Company to identify existing
therapeutic drugs which typically have been marketed for a number of years,
have established safety profiles and can be developed for new clinical
indications or with improved profiles in their existing clinical indications.
In this way, the Company seeks to reduce the risk, time and cost of new
product development as compared to the development of new chemical entities.
AGI is developing a range of product candidates to treat a variety of prevalent GI diseases and disorders, including irritable bowel syndrome, dyspeptic symptoms, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The Company is targeting areas of the GI therapeutic drug products market for its product candidates where there are currently unmet medical needs or where the effectiveness of existing drug therapies can be further improved.
The Company has five active clinical stage product candidates which are either isomers or novel drug delivery formulations of existing approved drugs and which have established safety and tolerability profiles in their currently approved clinical indications.
For further information please see www.agitherapeutics.com
Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research which is, by nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue.